Key Inclusion Criteria:

          1. Histologically or cytologically proven metastatic or locally advanced disease.
             Specifically:

             -patients with NSCLC, must have measurable disease by RECIST v1.1 criteria

          2. Must provide study-related tumor specimens;

          3. ECOG(PS) 0-1;

          4. Estimated Life Expectancy > 3 months;

          5. Adequate bone marrow (BM), renal, hepatic and metabolic function.

        Key Exclusion Criteria:

          1. Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine
             therapy, cytotoxic agents, targeted small molecule therapy or any investigational
             anticancer small molecule drugs within 2 weeks prior to the start of study treatment
             (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal
             antibodies within 4 weeks prior to the start of study treatment;

          2. Known symptomatic central nervous system (CNS) metastases requiring steroids.

          3. Diagnosis of any other malignancy within 2 years prior to enrollment;

          4. Vaccination within 4 weeks of the first dose of study treatment is prohibited except
             for administration of inactivated vaccines;

          5. Current use of immunosuppressive medication at study entry;

          6. Active or prior autoimmune disease that might deteriorate with receiving an
             immunostimulatory agent;

          7. Acute or chronic infections requiring systemic therapy;

          8. Known history of autoimmune colitis, inflammatory bowel disease, pneumonitis,
             pulmonary fibrosis;

          9. Known intolerance to checkpoint inhibitor therapy, defined by the occurrence of an AE
             leading to drug discontinuation;

         10. Participation in other studies involving investigational drug(s) within 28 days prior
             to study entry and/or during study participation.